Connect with us

Markets & Industry

Psychedelic expansion for cannabis company Little Green Pharma

The granting of a Schedule 9 licence for the supply of psilocybin clears a major hurdle for the company to enter the psychedelics sector. 



Psychedelic expansion for cannabis company Little Green Pharma

Little Green Pharma has been granted a licence to supply psilocybin from the Western Australia Government Department of Health. 

Australia’s first medical cannabis producer Little Green Pharma is expanding into psychedelic medicines, announcing it has been granted a Schedule 9 licence from the Western Australia Government Department of Health to supply psilocybin to eligible licence holders under the Medicines and Poisons Act 2014 (Western Australia).

The company says it has created a specially formed subsidiary to investigate the research developments in psychedelic medicines and the evolving regulations around the compounds in Australia.

Mushroom cultivation and supply

Since its founding in 2016, Little Green Pharma has made significant investments in cannabis product development, sales and marketing and cultivation capabilities. It was the first Australian company to provide Australian-grown cannabis medicines to patients in the country, having been granted a Therapeutic Goods Administration (TGA) Good Manufacturing Practices (GMP) licence for its manufacturing facility in 2020. 

The company, which has an extensive history producing and managing Schedule 9 drugs through its current cannabis operations, says that the recent granting of a Schedule 9 licence for the supply of psilocybin clears a major hurdle for it to enter the field of psychedelics. 

It will be utilising its existing investment in cultivation and drug manufacturing infrastructure and its experience and expertise in botanical drug-based products to cultivate psilocybin mushrooms for use in medical research – hoping to extend its current GMP licence to cover psilocybin manufacture.

Little Green Pharma managing director, Fleta Solomon, commented: “The field of psychedelics is a logical fit with our long term stated goals of solving real patient problems and transforming their lives. 

See also  New plant medicine retreat series launched in Jamaica

“We have developed so much experience over the years through the cannabis industry and we genuinely believe we can now bring that to bear on the development of the psychedelics field in Australia. The existing investment in our West Australian cannabis cultivation and manufacturing facility means we can meaningfully enter the field with minimal incremental capital spend.”

The company is also making headway to sponsoring a ground-breaking Perth-based clinical trial into psilocybin-assisted psychotherapy.


Read more: UK scientists to research use of psilocybin in end-of-life support

Markets & Industry

Partnership aims to optimise patient outcomes in psychedelic clinical trials

Beckley Psytech and Ksana Health will be building on digital strategy to deliver optimised patient outcomes.



Partnership aims to optimise patient outcomes in psychedelic clinical trials

The partnership is aiming to collect and analyse digital biomarkers to identify signs of response and relapse in Beckley’s upcoming 5-MeO-DMT Phase 2 clinical trials.

Beckley Psytech and Ksana Health’s partnership will support the collection and analysis of digital behavioural data in the  clinical trials. 

Through the partnership, Beckley Psytech aims to track novel, predictive digital biomarkers to follow patient progress in the trials, which will be evaluating the use of 5-MeO-DMT in combination with psychotherapy in the treatment of treatment resistant depression (TRD).

See also  Beckley Psytech collaboration to develop next-gen psychedelic medicines

CEO of Beckley Psytech, Cosmo Feilding Mellen, said: “This partnership with Ksana Health further supports our strategy to develop an integrated psychedelic treatment model, ensuring that patients are continuously supported throughout their treatment journey. 

“We look forward to working with Ksana Health and exploring how their state-of-the-art digital technology can help support patient safety and response in our upcoming Phase 2 clinical trials.”

Using Ksana Health’s Effortless Assessment Research System (EARS), an end-to-end solution for mobile sensing, Beckley will collect passive mobile device metadata from clinical trial participants’ smartphones, in order to identify individual signals of potential response and relapse. 

Co-founder and CEO of Ksana Health, Dr Nick Allen, commented: “Psychedelic treatments are offering exciting new approaches to recovery from mental disorders. However, we need rigorous clinical trials to ensure that this promise is realised. 

See also  Beckley Psytech doses first patients in novel 5-MeO-DMT study

“We are therefore very excited to partner with Beckley Psytech to help them build out their digital strategy. By using our continuous behavioural health measurement tools, we can help Beckley Psytech to understand each patient’s journey more deeply, which will ultimately allow for more effective and personalised treatments.”

The company has stated that this latest partnership further strengthens its digital strategy to develop personalised, end-to-end treatment programmes for patients in areas of significant unmet medical need.

Continue Reading

Markets & Industry

Patent application filed for ketamine as behavioural addiction treatment



Patent application filed for ketamine as behavioural addiction treatment

Awakn Life Sciences has filed a Patent Cooperation Treaty (PCT) application for the treatment of behavioural addictions with ketamine and ketamine-assisted psychotherapy. 

The successful completion of Awakn’s behavioural addictions study was announced last week and the data provided from the study was used in the patent filing. 

The pilot study investigated ketamine as a potential new treatment approach for Gambling Disorder, Internet Gaming Disorder, Compulsive Sexual Behavior Disorder and Binge Eating Disorder.

The PCT covers all behavioural addictions or any recognised disorder or condition with similar compulsive symptoms to those in the study. If granted, the patent claims would give Awakn exclusive rights to use ketamine and ketamine-assisted therapy for the treatment of behavioural addictions.

Awakn CEO, Anthony Tennyson, commented: “Today’s news demonstrates our focus on researching, developing and commercialising therapeutics to treat addiction.  

“A core part of our efforts is to continually strengthen our IP portfolio as we work to bring effective therapies to chronic addiction sufferers in desperate need. 

“To be forging a path to find an effective treatment for such a vast unmet medical need is critical and an effort we are very proud to be a part of.”

With no effective pharmacological treatments available globally at present for behavioural addictions, the study results and the patent filing position Awakn at the forefront of the industry at a time when rates of behavioural addictions are increasing at an alarming pace and sufferers have few treatment options which deliver poor outcomes.

The promising results from the pilot study showed a reduction of symptoms for some participants, with some participants no longer meeting the criteria for a diagnosis. Some individuals also showed a reduction of the symptoms of a comorbid psychiatric condition, such as depression or anxiety. The treatment was also well tolerated with no safety concerns.

Gambling Disorder, Internet Gaming Disorder, and Binge Eating Order are all recognised in the DSM-5, which is a diagnostic tool that serves as the principal authority for psychiatric diagnoses in the US, and affect up to 450 million, 235 million and 100 million people respectively. While Compulsive Sexual Behavior Disorder, which is included in the ICD-11, affects up to 350 million[4] people. 

The ICD-11 was developed by the World Health Organization (WHO) and is the global standard for recording health information and causes of death. Current standard of care for all of these conditions is poor.

Continue Reading

Markets & Industry

Top UK and European academics join Clerkenwell Health advisory board

Renowned academics in the field of psychedelics from leading European universities will be joining clinical research organisation Clerkenwell Health.



Top UK and European academics join Clerkenwell Health advisory board

Clerkenwell Health is expanding its pan-European advisory board with the addition of Dr David Erritzoe, Dr Dea Siggaard Stenbæk, Dr Kim Kuypers and Dr James Stone from Danish, Dutch and British universities.

With psychedelic research flourishing in Europe, Clerkenwell Health says it is building connections between commercial research organisations and academic institutions. 

The expansion of its advisory board will give the company access to knowledge and networks from some of the most prestigious European universities – working to fulfil the company’s mission to create a more vibrant psychedelic clinical trial ecosystem and foster wider sharing of best practices across Europe.

Discover how Clerkenwell Health is developing a gold standard for psychedelic care

Chaired by Dr Henry Fisher, the Clerkenwell Health CSO, the board will focus on clinical research and therapy, with its new members bringing expertise in areas of psychotherapy, psychopharmacology, mental health, experimental medicine and psychedelics.

Speaking to Psychedelic Health, CEO of Clerkenwell Health, Tom McDonald, said: “The UK is an attractive location to undertake psychedelic drug development as the government are opening up innovation pathways and championing clinical research.

“We are excited to be joined in our work exploring psychedelics-assisted therapy here in the UK with leading experts from prestigious European universities. Their involvement ensures we have a variety of expert opinions to shape innovative trial designs whilst preparing a platform for European expansion in the coming years.”

See also  Clerkenwell Health is launching a free UK psychedelic therapist training programme

With an aim to support the commercial research ecosystem in the UK and Europe, the new board additions place Clerkenwell Health as an ideal partner to support drug developers wishing to conduct trials in European countries.

CSO of Clerkenwell Health, Dr Henry Fisher, stated: “I am delighted to be able to bring together such high calibre advisors into the Clerkenwell Health scientific advisory board. These researchers are leaders in their respective fields in Europe and are shaping the direction of clinical and fundamental research with psychedelics. 

“This gives us access to the knowledge and network built in some of the most prestigious universities from Copenhagen to Maastricht and London, and it is a privilege to be able to consult with these figures on our own research.”

Meet the advisory board

Dr David Erritzoe is clinical director and deputy head of the Centre for Psychedelic Research at Imperial College London.

Erritzoe is currently investigating brain mechanisms and therapeutic potential of MDMA, ketamine and classic psychedelics, and is clinical senior lecturer in general psychiatry in Centres for Neuropsychopharmacology and Psychedelic Research at Imperial, as well as consultant psychiatrist at St Charles Hospital, CNWL Mental Health NHS Foundation Trust. Erritzoe also heads a NHS-based research clinic at St Charles Hospital, the CIPPRes Clinic.

Dr Dea Siggaard Stenbæk is an associate professor at University of Copenhagen and Copenhagen University Hospital. 

Stenbæk’s research mainly focuses on neuropsychopharmacological effects of the 5-HT2A receptor agonist psilocybin. She collaborates with the Centre for Psychedelic Research at Imperial College London and is currently an honorary clinical research fellow in this group. As the clinical lead, she works on a study of psilocybin as a treatment for obsessive compulsive disorder.

Dr Kim Kuypers is an associate professor at Maastricht University. Her PhD focused on memory and risk-taking during MDMA intoxication. 

Kuypers’ main goal is to understand the neurobiology underlying flexible cognition, empathy and wellbeing. To accomplish this she uses a psychopharmacological model, studying the (sub)acute and longer-lasting effects of psychedelics on these behaviours and their underlying biology.

Dr James Stone worked as a clinical senior lecturer at the Institute of Psychiatry, Psychology and Neuroscience at King’s College London, with a focus on experimental medicine and clinical trials. 

During his time there, Stone set up the ketamine clinic at the Maudsley Hospital for patients with treatment-resistant depression. He also worked at Imperial College London as a senior lecturer, working as co-director of the intercalated BSc in neuroscience as well as continuing research into the role of glutamatergic abnormalities in psychosis.

Continue Reading


Psychedelic Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. We do not provide medical advice or promote the personal use of psychedelic compounds. Please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2021 H&W Media Ltd.